Clovis Oncology (NASDAQ:CLVS – Get Rating) is set to post its quarterly earnings results before the market opens on Monday, August 8th. Analysts expect Clovis Oncology to post earnings of ($0.41) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Clovis Oncology (NASDAQ:CLVS – Get Rating) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The company had revenue of $34.25 million for the quarter, compared to analysts’ expectations of $37.03 million. During the same quarter last year, the firm posted ($0.64) earnings per share. On average, analysts expect Clovis Oncology to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Clovis Oncology Trading Up 1.2 %
Shares of NASDAQ CLVS opened at $1.66 on Friday. The stock has a market cap of $238.84 million, a price-to-earnings ratio of -0.79 and a beta of 0.45. Clovis Oncology has a 52 week low of $0.58 and a 52 week high of $5.06. The company’s 50-day moving average price is $1.60 and its 200 day moving average price is $1.70.
Institutional Trading of Clovis Oncology
Analysts Set New Price Targets
Separately, HC Wainwright lowered shares of Clovis Oncology from a “buy” rating to a “neutral” rating in a report on Friday, May 6th.
About Clovis Oncology
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.